Therapeutic Response

v::ALK status confers therapeutic sensitivity to Ensartinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Ensacove (ensartinib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.